GEOFFREY DOUGLAS BLOCK MD
Prescription History 1942208608
Internal Medicine - Gastroenterology in Rancho Mirage, CA


Quality Rating: 97.64 out of 100 score

NPI Status: Active since July 07, 2005

Contact Information

39700 BOB HOPE DR
SUITE 101
RANCHO MIRAGE, CA
ZIP 92270
Phone: (760) 773-2882

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for GEOFFREY DOUGLAS BLOCK MD, an active Gastroenterology specialist practicing in Rancho Mirage, CA. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 202 documented patient claims. Among these therapy options, the most frequently utilized medication is Tacrolimus, which accounts for 90 claims alone.

Medication Index


Amlodipine Besylate

Generic Formulation: Amlodipine BesylateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 13.0
Days Supply 390
CA State Average Benchmarks
Peer Average Claims138.0
Peer Average 30-Day Fills343.8
Peer Average Days Supply10,229
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 92.0% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.39

State Avg Cost Per Claim

$9.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.

Therapeutic Applications

Amlodipine is used with or without other medications to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Amlodipine belongs to a class of drugs known as calcium channel blockers. It works by relaxing blood vessels so blood can flow more easily. Amlodipine is also used to prevent certain types of chest pain (angina). It may help to increase your ability to exercise and decrease the frequency of angina attacks. It should not be used to treat attacks of chest pain when they occur. Use other medications (such as sublingual nitroglycerin) to relieve attacks of chest pain as directed by your doctor.

Epclusa

Generic Formulation: Sofosbuvir/VelpatasvirSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 60
30-Day Fills 60.0
Days Supply 1,680
CA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.5
Peer Average Days Supply684
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 150.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,599,040.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$26,650.68

State Avg Cost Per Claim

$18,018.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is a combination of sofosbuvir and velpatasvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice safer sex (including the use of latex condoms) to lower the risk of passing the virus to others.

Fluconazole

Generic Formulation: FluconazoleSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 17.0
Days Supply 510
CA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills24.1
Peer Average Days Supply354
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $595.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$54.11

State Avg Cost Per Claim

$26.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.

Therapeutic Applications

Fluconazole is used to treat vaginal yeast infections. It works by stopping the growth of common types of vaginal yeast (fungus). This medication belongs to a class of drugs called azole antifungals.

Mycophenolate Mofetil

Generic Formulation: Mycophenolate MofetilSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 18.0
Days Supply 540
CA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills50.9
Peer Average Days Supply1,505
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.6% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,703.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$141.97

State Avg Cost Per Claim

$139.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.

Therapeutic Applications

Mycophenolate is used in combination with other medications to keep your body from attacking and rejecting your transplanted organ (such as kidney, liver, heart). It belongs to a class of medications called immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own.

Sofosbuvir-Velpatasvir

Generic Formulation: Sofosbuvir/VelpatasvirSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 18
30-Day Fills 19.8
Days Supply 560
CA State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.2
Peer Average Days Supply397
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 28.6% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $171,195.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,510.84

State Avg Cost Per Claim

$8,361.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is a combination of sofosbuvir and velpatasvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice safer sex (including the use of latex condoms) to lower the risk of passing the virus to others.

Tacrolimus

Generic Formulation: TacrolimusSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 90
30-Day Fills 139.3
Days Supply 4,180
CA State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills53.1
Peer Average Days Supply1,540
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 136.8% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,740.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$108.23

State Avg Cost Per Claim

$222.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.

Therapeutic Applications

Tacrolimus is used with other medications to prevent rejection of a kidney transplant. This medication belongs to a class of drugs known as immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like GEOFFREY DOUGLAS BLOCK MD provides transparency into local medical care patterns within Rancho Mirage, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Gastroenterology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.